The population with type 2 DM (DM2) is highly heterogeneous, representing an important challenge for healthcare professionals. The therapeutic choice should be individualized, considering the functional status, frailty, the occurrence of comorbidities, and the preferences of patients and their caregivers. New evidence on the cardiovascular and renal protection of specific therapeutic groups and on the usefulness of new technologies for DM2 management, among other aspects, warrant an update of the consensus document on the DM2 in the elderly that was published in 2018.
Keywords: Antidiabetic treatment; Diabetes mellitus tipo 2; Edad avanzada; Elderly; Fragilidad; Frailty; Technology applied to diabetes; Tecnología aplicada a la diabetes; Tratamiento antidiabético; Type 2 diabetes mellitus.
Copyright © 2022 The Authors. Published by Elsevier España, S.L.U. All rights reserved.